Tecentriq Hybreza savings card: as little as $0 a treatment with commercial insurance

How to pay the least

Ask for the cash price

Tecentriq Hybreza

This medicine is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Ask your pharmacy for Tecentriq Hybreza’s cash price, and one or two other pharmacies too.
Tecentriq Hybreza’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Genentech Patient Foundation. Do not have insurance coverage for their Genentech medicine and their household makes less than $150,000 per year Or call (888) 941-3331.

See if you qualify

Compare every option

Brand nameTecentriq Hybreza

Authorized genericatezolizumab and hyaluronidase-tqjs

Regular genericatezolizumab and hyaluronidase-tqjs

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as the brand?

The original

–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

The card takes up to $25,000 a year off your co-pay.

Or call 1-888-249-4918.

In the maker’s words

“With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance may pay as little as $0 per treatment for TECENTRIQ HYBREZA.”

From the maker’s offer on tecentriq.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Tecentriq Hybreza itself, from the same company, sold without the brand name, and usually for less. For now Tecentriq Hybreza is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

This medicine is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated:

Non-Small Cell Lung Cancer (NSCLC)

as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test.
for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations.
in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA.

Small Cell Lung Cancer (SCLC)

in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
in combination with lurbinectedin, for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ HYBREZA or intravenous atezolizumab, and carboplatin plus etoposide.

Hepatocellular Carcinoma (HCC)

in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy.

Melanoma

in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test.

Alveolar Soft Part Sarcoma (ASPS)

for the treatment of adult patients and pediatric patients (12 years of age and older who weigh 40 kg or greater) with unresectable or metastatic ASPS.

Muscle Invasive Bladder Cancer (MIBC)

as adjuvant treatment of adult patients with MIBC after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

Mismatch Repair– Deficient Colon Cancer

in combination with a fluoropyrimidine and oxaliplatin, is indicated for the adjuvant treatment of adult patients and pediatric patients (12 years of age and older who weigh 40 kg or greater) with Stage III, mismatch repair deficient (dMMR) colon cancer.

Source: the FDA label for Tecentriq Hybreza (Genentech, Inc.), October 13, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tecentriq-hybreza/